Prostate cancer clinical trial hits major milestone

Posted 15th January 2024

A prostate cancer clinical research trial being led nationally at The Clatterbridge Cancer Centre is celebrating signing up more than 400 local participants.

The PIVOTALboost clinical trial is headed up by Clatterbridge consultant oncologist Professor Isabel Syndikus, who is Chief Investigator.

The trial aims to recruit 2,229 patients across 41 trial sites in the UK and Clatterbridge’s uro-oncology consultants and its research team have enrolled more than 400 people since the study launched in January 2018.

The clinical trial is open to men receiving radical radiotherapy for localised prostate cancer with higher risk features.

Researchers want to find out whether radiotherapy with focal boosts improves on the outcome for patients.

The study is also designed to look at side effects and discover more about the quality of life that patients have during and after treatment.

Prof Syndikus, pictured, said: “We are delighted that Clatterbridge has been able to recruit more than 400 patients to PIVOTALboost. It is an important study for the future of treatment for prostate cancer.

“I would like to thank the patients, my wonderful colleagues and hard-working research team at Clatterbridge who have enabled us to reach this impressive milestone.”